Uncategorized

Alnylam hops on AI train with up to $2B Inceptive partnership

Published

on

Alnylam Pharmaceuticals will leverage Inceptive Nucleics’ generative machine learning models to accelerate the development of RNA interference therapies.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version